What is I-MOVE+?
Since 2015, I-MOVE+ measures the effectiveness and impact of vaccines against influenza and invasive pneumococcal infections in people over 64 years of age in Europe.
I-MOVE+ aims to identify, test and compare the types of epidemiological studies that can be used to measure the vaccine effectiveness of influenza and pneumococcal vaccines in real time. These studies are carried out during seasonal influenza epidemics and using IIP surveillance systems. The results are intended to guide influenza and pneumococcal vaccine strategies. For influenza, the results are used to adapt vaccination strategies and contribute to the composition of the vaccine used the following season.
Epiconcept is coordinating this H2020 project which brings together 20 European partners (national public health institutes) and more than 50 study sites.